What a coincidence. Would like to think that Dr. Sinclair who's US office is in San Francisco, knows Ms. Trombley of Lyrica Therapeutics and Carolyn Bertozzi of Stanford U. and now Eli Lilly. More importantly, Dr. Sinclair or someone at ATH needs to acquaint them with our small molecule drugs and what they might bring to the party. Have always hoped for a partnership or buyout with Eli Lilly which should be an excellent fit, especially now.
Pivalde, please feel free to forward the Endpoint News link to any of your ATH/ATHE contacts. Thank you.
Today's Endpoints News Lead Article Regarding Eli Lilly Actions and Plans
-
- There are more pages in this discussion • 27 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add ATH (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
0.3¢ |
Change
0.000(0.00%) |
Mkt cap ! $15.96M | |||
| Open | High | Low | Value | Volume |
| 0.3¢ | 0.3¢ | 0.3¢ | $2.564K | 854.8K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 61 | 80531900 | 0.2¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 0.3¢ | 2803048 | 3 |
View Market Depth
| Last trade - 10.19am 18/09/2024 (20 minute delay) ? |
| ATH (ASX) Chart |